A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript

Abstract The development of imatinib is a milestone in the treatment of chronic myeloid leukemia (CML), and its therapeutic effect has been extensively investigated in CML patients carrying M-bcr and m-bcr BCR/ABL fusion transcripts. However, our knowledge about its therapeutic effect on CML patient...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genetics and cytogenetics 2007-07, Vol.176 (2), p.166-168
Main Authors: Li, Xiaoqing, Yang, Jing, Chen, Xiangjun, Liu, Jun, Li, Hongrui, Zheng, Jine, He, Yanli, Chen, Zhong, Huang, Shiang
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Benzamides
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Cytogenetic Analysis
Disease Progression
Exons
Female
Gene Expression Regulation, Leukemic - drug effects
Genes, abl - drug effects
Genes, abl - genetics
Hematology, Oncology and Palliative Medicine
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Medical Education
Middle Aged
Piperazines - therapeutic use
Pyrimidines - therapeutic use
RNA, Messenger - drug effects
RNA, Messenger - metabolism
Time Factors
Translocation, Genetic
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The development of imatinib is a milestone in the treatment of chronic myeloid leukemia (CML), and its therapeutic effect has been extensively investigated in CML patients carrying M-bcr and m-bcr BCR/ABL fusion transcripts. However, our knowledge about its therapeutic effect on CML patients with rare BCR/ABL fusion transcripts e19a2(u-bcr) remains sparse. Here, we report on two CML patients with e19a2 transcripts who rapidly progressed into the accelerated phase, further confirming the possibility that 19a2 might be associated with an unfavorable prognosis in CML. Moreover, these patients showed early response to imatinib treatment. Our study highlights the clinical potential of imatinib for this patient subgroup.
ISSN:0165-4608
1873-4456
DOI:10.1016/j.cancergencyto.2007.04.013